MA-VALAMIS
24.9.2020 10:02:15 CEST | Business Wire | Press release
Valamis , the global leader in digital learning technologies and workforce development, published results from the “Global Survey on the State of Learning & Development (L&D) in the Workplace Report ,” which includes over 3000 people across more than 20 industries were surveyed from entry-level to C-Suite executives in organizations from Finland, France, Germany, Netherlands, Sweden, the US, and the UK.
Valamis conducted its 2nd annual “Global Survey on the State of Learning & Development (L&D) in the Workplace Report”, collecting insight into the shifting global priorities, challenges, behaviors, attitudes, and technologies in use for corporate learning and development, with additional research into the impact of COVID-19.
The importance of learning & development in the workforce
Findings from the survey show that roughly 93% of respondents globally believe updating knowledge and skills are important to an organization’s success and more than 50% of executives and the C-Suite value skills development as extremely important to an organization’s future success. Although the importance of learning and development has been recognized in every country surveyed, over 74% of respondents believe their organizations are actively encouraging the workforce to develop their skills and nearly 56% of respondents had a dedicated person or team responsible for learning and development at their organization.
Time to learn
Despite the globally acknowledged importance of learning and development, for the second consecutive year conducting the survey, the biggest challenge plaguing learning and development within organizations is a lack of time or perceived time affluence with regards to learning. 48% of respondents globally denoted a lack of time as the biggest challenge for learning and development. Interestingly, survey participants at the executive and C-suite level note that they use their digital learning environment the most frequently (Nearly 30% using it every day) of all survey participants.
Tools in place for corporate learning
25% of respondents specify not having the right tools in place as one of the top three challenges for learning & development. Approximately 15% of respondents demarcate that their organization does not have a digital learning environment in place at their organization, and the Netherlands has the highest percentage of respondents of all the countries surveyed that specify they have a Learning Management System (LMS) (24%) or Learning Experience Platform (LXP or LEP) (20%) in place, whereas the United States (28%), United Kingdom (29%), and Germany (28%) have the highest percentages of respondents relying on online courses or Massive Open Online Courses (MOOCs). Finland has the highest number of respondents (18%) that suggest their organization has no digital learning tools in place.
COVID-19 & L&D
Approximately 70% of executives within the global survey express they value digital learning and development more as a result of COVID-19, and over 67% of all global participants in the survey believe digital learning and development can help minimize the effects of shocks and stresses of future events.
“2020 has been a challenging year for many organizations and individuals worldwide. Our global survey on the state of learning and development highlights an internationally growing acknowledgment from the C-suite that L&D is critical to the success of their organizations, and with the right tools in place organizations can adapt and reskill in the face of unforeseen events,” said Janne Hietala, Chief Visionary Officer, Valamis.
Download the report here
.
*Please note the survey results are in English
About Valamis
Valamis is a digital learning company specializing in workforce development, and the developer of Valamis - Learning Experience Platform. Valamis' customers are large organizations spanning all industries—predominantly finance and insurance, complex manufacturing, and professional services. Headquartered in Joensuu, Finland, Valamis operates internationally with offices in the US, the UK, Germany, the Netherlands, Russia, and India.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
